SCHEMBL25826884

SCHEMBL25826884

CCOC(=O)c1csc([C@H](N)C[C@@H](NC(=O)OC(C)(C)C)C(C)C)n1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 6/20 0.66
PTPRB P23467 4/20 0.44
RAB9A P51151 4/20 0.43
NPC1 O15118 3/20 0.43
MAPT P10636 2/20 0.43
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KMT2A Q03164 1/20 0.43
CA1 P00915 2/20 0.43
CA2 P00918 2/20 0.43
CA7 P43166 2/20 0.43
CYP1A2 P05177 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
GAA P10253 1/20 0.41
HSP90AA1 P07900 1/20 0.39
MAPK1 P28482 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
CA4 P22748 1/20 0.37
CA9 Q16790 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24140870 1.00 ABCB1 (0.66) ABCB1PTPRBRAB9ANPC1MAPT
SCHEMBL24140388 0.89 ABCB1 (0.67) ABCB1PTPRBRAB9ANPC1MAPT
SCHEMBL28923528 0.89 ABCB1 (0.67) ABCB1PTPRBRAB9ANPC1MAPT
SCHEMBL24140416 0.89 ABCB1 (0.67) ABCB1PTPRBRAB9ANPC1MAPT
SCHEMBL24140377 0.86 ABCB1 (0.64) ABCB1PTPRBRAB9ANPC1MAPT
SCHEMBL10041887 0.86 ABCB1 (0.64) ABCB1PTPRBRAB9ANPC1MAPT
SCHEMBL24140376 0.86 ABCB1 (0.64) ABCB1PTPRBRAB9ANPC1MAPT
SCHEMBL25826890 0.85 ABCB1 (0.62) ABCB1PTPRBRAB9ANPC1MAPT
SCHEMBL24140420 0.85 ABCB1 (0.62) ABCB1PTPRBRAB9ANPC1MAPT
SCHEMBL24140864 0.84 ABCB1 (0.61) ABCB1PTPRBRAB9ANPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230414775-A1 TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES REGENERON PHARMACEUTICALS, INC. 2023-12-28 US disclosed
WO-2023129518-A1 TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES REGENERON PHARMACEUTICALS, INC. (US) 2023-07-06 WO disclosed
EP-4171653-A2 TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES Regeneron Pharmaceuticals, Inc. (US) 2023-05-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230414775-A1 TUBULYSINS AND PROTEIN-TUBULYSIN CONJUGATES SDCBP, TEK, TEKT1 ABCB1 895/4885PTPRB 570/4885RAB9A 1892/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.